1. Home
  2. ALVO vs KALV Comparison

ALVO vs KALV Comparison

Compare ALVO & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alvotech

ALVO

Alvotech

HOLD

Current Price

$3.54

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$19.25

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALVO
KALV
Founded
2013
N/A
Country
Luxembourg
United States
Employees
1460
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ALVO
KALV
Price
$3.54
$19.25
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$8.00
$32.60
AVG Volume (30 Days)
366.2K
1.1M
Earning Date
05-06-2026
07-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
$13.28
$185.42
Revenue Next Year
$18.63
$59.23
P/E Ratio
$18.20
N/A
Revenue Growth
N/A
495.66
52 Week Low
$3.03
$9.83
52 Week High
$11.85
$21.31

Technical Indicators

Market Signals
Indicator
ALVO
KALV
Relative Strength Index (RSI) 48.90 50.85
Support Level $3.03 $14.66
Resistance Level $3.93 $21.25
Average True Range (ATR) 0.18 1.09
MACD 0.00 -0.23
Stochastic Oscillator 51.04 21.85

Price Performance

Historical Comparison
ALVO
KALV

About ALVO Alvotech

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: